10-Gene Sequencing Panel Could Identify Patients With MDS Likely to Relapse After Allogeneic HCT
Investigators tested the utility of ultra-deep genomic testing to predict relapse in patients with myelodysplastic syndrome initiating conditioning therapy for allogeneic hematopoietic cell transplant (alloHCT).